Literature DB >> 29952618

Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys.

Gregory T Collins1, Charles P France1.   

Abstract

Cocaine use disorder is a serious public health issue for which there is no effective pharmacotherapy. One strategy to speed development of medications for cocaine use disorder is to repurpose drugs already approved for use in humans based on their ability to interact with targets known to be important for addiction. Two such drugs, lorcaserin (Belviq; a drug with serotonin [5-HT]2C receptor agonist properties) and buspirone (Buspar; a drug with 5-HT1A receptor partial agonist and dopamine D3/D4 receptor antagonist properties) can produce modest decreases in cocaine self-administration in rhesus monkeys. The current study evaluated the effectiveness of mixtures of lorcaserin and buspirone (at fixed dose ratios of 3:1, 1:1, and 1:3 relative to each drug's ID50) to reduce responding for 0.032 mg/kg/inf cocaine under a progressive ratio schedule of reinforcement in 2 male and 2 female rhesus monkeys. Dose addition analyses were used to determine if the effects of the drug mixtures differed from those predicted for an additive interaction between lorcaserin and buspirone. Dose-dependent reductions of cocaine self-administration were observed when lorcaserin and buspirone were administered alone, as well as when they were administered as 3:1, 1:1, and 1:3 fixed ratio mixtures of lorcaserin + buspirone. The effects of the 1:1 mixture of lorcaserin + buspirone on cocaine self-administration were supraadditive, whereas the effects of 3:1 and 1:3 mixtures were additive. Together, these results indicate that a combination therapy containing a mixture of lorcaserin and buspirone might be more effective than either drug alone at treating cocaine use disorder. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29952618      PMCID: PMC6162158          DOI: 10.1037/pha0000209

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  51 in total

Review 1.  Glutamatergic agents for cocaine dependence.

Authors:  Charles Dackis; Charles O'Brien
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 2.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

3.  Individual differences in the effects of serotonergic anxiolytic drugs on the motivation to self-administer cocaine.

Authors:  J R Homberg; B Arends; G Wardeh; H S Raasø; A N M Schoffelmeer; T J de Vries
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 4.  Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.

Authors:  Guy A Higgins; Paul J Fletcher
Journal:  ACS Chem Neurosci       Date:  2015-04-14       Impact factor: 4.418

5.  Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.

Authors:  E V Gurevich; J N Joyce
Journal:  Neuropsychopharmacology       Date:  1999-01       Impact factor: 7.853

6.  Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement.

Authors:  Paul J Fletcher; Judy Sinyard; Guy A Higgins
Journal:  Pharmacol Biochem Behav       Date:  2010-07-16       Impact factor: 3.533

7.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

8.  The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.

Authors:  Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

Review 9.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

10.  Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys.

Authors:  Lisa R Gerak; Gregory T Collins; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-09-20       Impact factor: 4.030

View more
  12 in total

1.  Serotonin transporter protein in autopsied brain of chronic users of cocaine.

Authors:  Junchao Tong; Jeffrey H Meyer; Isabelle Boileau; Lee-Cyn Ang; Paul J Fletcher; Yoshiaki Furukawa; Stephen J Kish
Journal:  Psychopharmacology (Berl)       Date:  2020-06-03       Impact factor: 4.530

2.  Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys.

Authors:  Gregory T Collins; Agnieszka Sulima; Kenner C Rice; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2019-07-26       Impact factor: 4.530

3.  Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms.

Authors:  Ewa Galaj; Guo-Hua Bi; Hong-Ju Yang; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-08-19       Impact factor: 5.250

Review 4.  The Roles of Serotonin in Neuropsychiatric Disorders.

Authors:  Mahsa Pourhamzeh; Fahimeh Ghasemi Moravej; Mehrnoosh Arabi; Elahe Shahriari; Soraya Mehrabi; Richard Ward; Reza Ahadi; Mohammad Taghi Joghataei
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

Review 5.  Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2020-08-24       Impact factor: 7.853

Review 6.  Converging vulnerability factors for compulsive food and drug use.

Authors:  Katherine M Serafine; Laura E O'Dell; Eric P Zorrilla
Journal:  Neuropharmacology       Date:  2021-04-20       Impact factor: 5.273

Review 7.  Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders.

Authors:  Ken W Grasing; Kim Burnell; Alok De
Journal:  Behav Pharmacol       Date:  2022-03-23       Impact factor: 2.277

8.  Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.

Authors:  Noelle C Anastasio; Dennis J Sholler; Robert G Fox; Sonja J Stutz; Christina R Merritt; James M Bjork; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropharmacology       Date:  2020-02-14       Impact factor: 5.250

Review 9.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

10.  5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.

Authors:  Caroline A Arout; Ziva D Cooper; Stephanie Collins Reed; Richard W Foltin; Sandra D Comer; Frances R Levin; Margaret Haney
Journal:  Addict Biol       Date:  2021-01-03       Impact factor: 4.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.